首页> 外文期刊>International journal of urology: official journal of the Japanese Urological Association >Telomerase activity in renal cell carcinoma by modified telomeric repeat amplification protocol assay.
【24h】

Telomerase activity in renal cell carcinoma by modified telomeric repeat amplification protocol assay.

机译:肾细胞癌中端粒酶活性的改良端粒重复扩增方案分析。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: Previous assessments by the conventional telomeric repeat amplification protocol have not been reliable for the quantitation of telomerase activity. We, therefore, determined telomerase activity in renal cell carcinoma (RCC) tissue by the modified sensitive telomeric repeat amplification protocol assay. METHODS: Telomerase activity was examined in 23 cases of RCC and in the adjacent normal kidney tissue, and assessed for associations with clinical and pathological variables of the disease. RESULTS: The linearity and quantitation of the modified method was confirmed. Mean telomerase activity of RCC (1987.889 +/- 1232.801 units) was significantly greater than that of normal renal tissue (173.467 +/- 241.893 units) (P = 0.0001). Telomerase activity in RCC was, however, not associated with clinical or pathological variables such as clinical stage (P = 0.8941), grade (P = 0.8043) or pathological subtype (P = 0.9739). CONCLUSION: The results suggest that telomerase might play a crucial role in aninitial step of the development of RCC, but not in the progression of the disease.
机译:背景:传统的端粒重复扩增方案先前的评估对端粒酶活性的定量分析并不可靠。因此,我们通过改良的敏感端粒重复扩增方案测定法确定了肾细胞癌(RCC)组织中的端粒酶活性。方法:检查了23例RCC和邻近正常肾脏组织中的端粒酶活性,并评估了与该疾病的临床和病理变量的关联。结果:证实了改进方法的线性和定量。 RCC的平均端粒酶活性(1987.889 +/- 1232.801单位)显着大于正常肾组织的平均端粒酶活性(173.467 +/- 241.893单位)(P = 0.0001)。但是,RCC中的端粒酶活性与临床或病理变量(例如临床分期(P = 0.8941),等级(P = 0.8043)或病理亚型(P = 0.9739)无关。结论:结果提示端粒酶可能在RCC发生的最初步骤中起关键作用,但在疾病的进展中不起作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号